Literature DB >> 10160092

Clinical issues related to the costs of alcoholism.

M O Howard1, R W McGuffin, A J Saxon, K L Sloan, R D Walker.   

Abstract

Alcohol (ethanol) use disorders are prevalent in many countries and are associated with significant social and health costs. Little is known, however, about the comparative cost effectiveness of treatments for alcoholism. Pharmacoeconomic evaluations are largely (if not wholly) absent from the alcoholism treatment outcome database. We discuss pharmacological approaches to the treatment of alcohol withdrawal and dependence, describing agents that ameliorate withdrawal symptoms, deter alcohol consumption, reduce alcohol craving and produce conditioned alcohol aversion. Cost-relevant clinical considerations are elucidated and recommendations for cost-conscious pharmacological treatment of alcohol dependence are proffered.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 10160092     DOI: 10.2165/00019053-199609020-00005

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  75 in total

1.  Double-blind controlled trial comparing carbamazepine to oxazepam treatment of alcohol withdrawal.

Authors:  R Malcolm; J C Ballenger; E T Sturgis; R Anton
Journal:  Am J Psychiatry       Date:  1989-05       Impact factor: 18.112

2.  Predicting onset and chronicity of women's problem drinking: a five-year longitudinal analysis.

Authors:  S C Wilsnack; A D Klassen; B E Schur; R W Wilsnack
Journal:  Am J Public Health       Date:  1991-03       Impact factor: 9.308

3.  Comparative effectiveness and costs of inpatient and outpatient detoxification of patients with mild-to-moderate alcohol withdrawal syndrome.

Authors:  M Hayashida; A I Alterman; A T McLellan; C P O'Brien; J J Purtill; J R Volpicelli; A H Raphaelson; C P Hall
Journal:  N Engl J Med       Date:  1989-02-09       Impact factor: 91.245

Review 4.  Pharmacological treatment of alcohol intoxication, withdrawal and dependence: a critical review.

Authors:  B I Liskow; D W Goodwin
Journal:  J Stud Alcohol       Date:  1987-07

5.  Cost to industry of illnesses related to alcohol and smoking. A study of Telecom Australia employees.

Authors:  B Hocking; H Grain; I Gordon
Journal:  Med J Aust       Date:  1994-10-03       Impact factor: 7.738

Review 6.  Disulfiram-induced fulminating hepatitis: guidelines for liver-panel monitoring.

Authors:  C Wright; J A Vafier; C R Lake
Journal:  J Clin Psychiatry       Date:  1988-11       Impact factor: 4.384

7.  Propranolol versus diazepam in the management of the alcohol withdrawal syndrome: double-blind controlled trial.

Authors:  T M Worner
Journal:  Am J Drug Alcohol Abuse       Date:  1994       Impact factor: 3.829

8.  Disulfiram treatment of alcoholism. A Veterans Administration cooperative study.

Authors:  R K Fuller; L Branchey; D R Brightwell; R M Derman; C D Emrick; F L Iber; K E James; R B Lacoursiere; K K Lee; I Lowenstam
Journal:  JAMA       Date:  1986-09-19       Impact factor: 56.272

9.  Citalopram decreases desirability, liking, and consumption of alcohol in alcohol-dependent drinkers.

Authors:  C A Naranjo; C X Poulos; K E Bremner; K L Lanctôt
Journal:  Clin Pharmacol Ther       Date:  1992-06       Impact factor: 6.875

10.  Carbamazepine treatment for benzodiazepine withdrawal.

Authors:  R K Ries; P P Roy-Byrne; N G Ward; V Neppe; S Cullison
Journal:  Am J Psychiatry       Date:  1989-04       Impact factor: 18.112

View more
  1 in total

Review 1.  Acamprosate. A review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification.

Authors:  M I Wilde; A J Wagstaff
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.